Basit öğe kaydını göster

dc.contributor.authorCeyhan, Mehmet
dc.contributor.authorOzsurekci, Yasemin
dc.contributor.authorAykac, Kubra
dc.contributor.authorHacibedel, Basak
dc.contributor.authorOzbilgili, Egemen
dc.date.accessioned2019-12-10T10:36:17Z
dc.date.available2019-12-10T10:36:17Z
dc.date.issued2018
dc.identifier.issn2164-5515
dc.identifier.urihttps://doi.org/10.1080/21645515.2017.1371378
dc.identifier.urihttp://hdl.handle.net/11655/13936
dc.description.abstractThe present study aimed to determine the cost of childhood pneumococcal infections under 5years of age and to provide further data for future health economy studies. Electronic medical records of children diagnosed with meningitis caused by S. pneumoniae and all-cause pneumonia, and acute otitis media (AOM) between January 2013-April 2014 were retrospectively evaluated. Direct costs for the treatments of hospitalized patients (pneumonia and pneumococcal meningitis) including costs of healthcare services consisted of costs of hospital bed, examination, laboratory analyses, scanning methods, consultation, vascular access procedures, and infusion and intravenous treatments. Direct costs for patients (AOM) treated in outpatient setting included constant price paid for the examination and cost of prescribed antibiotics. Indirect costs included cost of work loss of parents and their transportation expenses. Data of 130 children with pneumococcal meningitis (n = 10), pneumonia (n = 53), and AOM (n = 67) were analyzed. The total median cost was Euro4,060.38 (direct cost: Euro3,346.38 and indirect cost: Euro829.18) for meningitis, Euro835.91 (direct cost: Euro480.66 and indirect cost: Euro330.09) for pneumonia, and Euro117.32 (direct cost: Euro17.59 and indirect cost: Euro99.73) for AOM. The medication cost (p = 0.047), indirect cost (p = 0.032), and total cost (p = 0.011) were significantly higher in pneumonia patients aged 36 months than those aged <36 months; however, direct cost of AOM were significantly higher in the patients aged <36 months (p = 0.049). Results of the present study revealed that the treatment cost was significantly enhanced for hospitalization and for advanced disease. Thus, preventive actions, mainly vaccination, should be conducted regularly.
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.isversionof10.1080/21645515.2017.1371378
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiotechnology & Applied Microbiology
dc.subjectImmunology
dc.titleEconomic Burden of Pneumococcal Infections in Children Under 5Years of Age
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalHuman Vaccines & Immunotherapeutics
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları
dc.identifier.volume14
dc.identifier.issue1
dc.identifier.startpage106
dc.identifier.endpage110
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster